The Steroid Receptor Superfamily

January 8-12, 1999
Renaissance Esmeralda Resort
Indian Wells (Palm Springs), CA

CONFERENCE CO-CHAIRPERSONS
Michael G. Rosenfeld / La Jolla, CA
Christopher K. Glass / La Jolla, CA

CONFERENCE PROGRAM

Keynote Session
Bruce M. Spiegelman / Boston, MA
Carl Wu / Bethesda, MD

Structure/Function of Nuclear Receptors
Michael V. Milburn / Research Triangle Park, NC
Roderick E. Hubbard / York, England
Marc Montminy / Boston, MA
Jan-Åke Gustafsson / Huddinge, Sweden
John Baxter / San Francisco, CA

Coactivators/Corepressors I
Charles D. Allis / Rochester, NY
Bert W. O'Malley / Houston, TX
Leonard P. Freedman / New York, NY

Orphans and Ligands
Steven A. Kliewer / Durham, NC
Thomas Perlmann / Stockholm, Sweden
Vincent Giguere / Montreal, Canada

Coactivators/Corepressors II
Mitchell A. Lazar / Philadelphia, PA
Shelley Berger / Philadelphia, PA
David D. Moore / Houston, TX

Receptors in Cancer and Leukemia
Richard A. Heyman / San Diego, CA
Malcolm G. Parker / London, England
Kelko Ozato / Bethesda, MD
Myles A. Brown / Boston, MA
Donald P. McDonnell / Durham, NC

Transcriptional Control Mechanisms
James T. Kadonaga / San Diego, CA
Yoshihiro Nakatani / Bethesda, MD
Alan P. Wolff / Bethesda, MD

Nuclear Receptors, Development, and Regulation
Ming-Jer Tsai / Houston, TX
Ronald M. Evans / La Jolla, CA
Günther Schütz / Heidelberg, Germany
Holly A. Ingraham / San Francisco, CA

Additional Speakers to be Announced

Application Deadline: November 23, 1998

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: meetings@aacr.org
Website: http://www.aacr.org
Featured on the cover of this issue is Kenneth R. Harrap, one of Britain's top leaders in the field of cancer chemotherapy. He has amassed an illustrious record of accomplishments over his 42-year career at the Institute of Cancer Research/Royal Marsden NHS Trust in Sutton, Surrey, England. Dr. Harrap began his career at the Institute as a Lecturer in Chemistry from 1956–64, during which time, he received his Ph.D. in Chemistry from London University in 1961. He then served as Head of the Leukaemia Biochemistry Group (1964–70), of the Department of Applied Biochemistry (1970–77), and of the Department of Biochemical Pharmacology (1977–82). From 1982–94, he was Chairman of the Drug Development Section before assuming the prestigious post of Director of the Institute's Cancer Research Campaign Centre for Cancer Therapeutics. As his career was advancing at the Institute, he also earned a D.Sc. in Pharmacology and Biochemistry from London University in 1977 and was appointed Professor of Biochemical Pharmacology at the University of London in 1983.

In October 1997, he retired from the directorship of the Cancer Research Campaign Centre, having contributed greatly to its reputation as the leading European academic institute for developmental cancer chemotherapy. As Director, he oversaw a staff of 85 people, including Ph.D.'s, M.D.'s, research and scientific officers, research nurses, data managers, graduate students, and administrative staff, and an annual budget of 3 million pounds, which is garnered each year from peer-reviewed program and project grants from both charitable and commercial funding sources. Dr. Harrap was responsible for directing and coordinating a multidisciplinary program of drug development that embraces synthetic organic chemistry, biochemistry, and preclinical and clinical pharmacology. Under his leadership, the research and development program encompassed the discovery and development of antimitobolite, anti-endocrine, antisense, gene/antibody/growth factor receptor-targeted, cell signaling-directed, and platinum-based agents, and this work continues today at the Centre. Much of the research is conducted with the partnership and collaboration of many pharmaceutical and chemical firms, an initiative fostered under Dr. Harrap's directorship.

Dr. Harrap's research focused on the development of platinum compounds and antimitobolites as anticancer agents. He has published over 400 papers, book chapters, reviews, meeting proceedings, and abstracts. His notable accomplishments have been the discovery of: Carboplatin, which is effective in testicular and ovarian cancer; JM216, the first orally administered platinum compound, which is currently in Phase-III trials; AMD 473, which is active in cisplatin-resistant tumors; and Tomudex, an antitumor thymidylate synthase inhibitor, which is used in the treatment of colon cancer and advanced colorectal cancer.

Upon his retirement in 1997, Dr. Harrap was appointed Emeritus Professor, but he is still highly active in the field. He serves on numerous advisory committees, editorial boards, and consultancies. He is a member of the Biochemical Society, the British Association for Cancer Research, the Royal Society of Chemistry, and the American Association for Cancer Research (AACR), of which he has been a member since 1978. In addition to having won the AACR Bruce F. Cain Memorial Award in 1995, he served on the Cain Award Committee for the Association in 1996.

His greatest honor was having the title of Commander of the Order of the British Empire bestowed upon him by her Majesty the Queen of England at Buckingham Palace on February 24, 1998. Other honors include the Queen’s Award for Technological Achievement in 1991; Life Fellow of the Cancer Research Campaign, 1994; the Barnett Rosenberg Award of the International Platinum Drug Society, 1995; the Cain Memorial Award of the New Zealand Cancer Society, 1996; and the St. Jude Children's Research Hospital Distinguished Lecturer in Pharmacology, 1996.

We extend our appreciation to V. Craig Jordan for providing the material for this cover feature.

Sidney Weinhouse